Historique
Bulletin de Périodique
Addiction , Vol.106, n°2 - February 2011
Paru le :
01/02/2011
Année
2011
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
• Proposals to trial deep brain stimulation to treat addiction are premature. Carter A., Hall W., p. 235-237.
• FOR DEBATE: The 'grass ceiling': limitations in the literature hinder our understanding of cannabis use and its consequences. Temple E.C., Brown R.F., Hine D.W., p. 238-244.
• Addiction research centres and the nurturing of creativity. RAND's Drug Policy Research Center. Reuter P., Pacula R.L., Caulkins J.P., p. 253-259.
• Conversation with Martin Jarvis. Jarvis M., p. 260-266.
• Can stand-alone computer-based interventions reduce alcohol consumption? A systematic review. Khadjesari Z., Murray E., Hewitt C., Hartley S., Godfrey C., p. 267-282.
• Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Ambermoon P., Carter A., Hall W.D., Dissanayaka N.N., O'Sullivan J.D., p. 283-293.
• How best to measure change in evaluations of treatment for substance use disorder. Marsden J., Eastwood B., Wright C., Bradbury C., Knight J., Hammond P., p. 294-302.
• Effects of restricting pub closing times on night-time assaults in an Australian city. Kypri K., Jones C., McElduff P., Barker D., p. 303-310.
• Per capita alcohol consumption and ischemic heart disease mortality in a panel of US states from 1950 to 2002. Kerr W.C., Karriker-Jaffe K., Subbaraman M., Ye Y., p. 313-322.
• Personal, family and social functioning among older couples concordant and discordant for high-risk alcohol consumption. Moos R.H., Schutte K.K., Brennan P.L., Moos B.S., p. 324-334.
• The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time. Howland J., Rohsenow D.J., Arnedt J.T., Bliss C.A., Hunt S.K., Calise T.V., et al., p. 335-341.
• The course of substance use disorders in patients with borderline personality disorder and Axis II comparison subjects: a 10-year follow-up study. Zanarini M.C., Frankenbur F.R., Weingeroff J.L., Reich D.B., Fitzmaurice G.M., Weiss R.D., p. 342-348.
• Decreased bone density in men on methadone maintenance therapy. Grey A., Rix-Trott K., Horne A., Gamble G., Bolland M., Reid I.R., p. 349-354.
• The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs. Beletsky L., Grau L.E., White E., Bowman S., Heimer R., p. 357-365.
• The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Tobin K.E., Kuramoto S.J., Davey-Rothwell M.A., Latkin C.A., p. 366-375.
• Cessation of groin injecting behaviour among patients on oral opioid substitution treatment. Senbanjo R., Hunt N., Strang J., p. 376-382.
• Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Linnet J., Moller A., Peterson E., Gjedde A., Doudet D., p. 383-390.
• Dizziness and the genetic influences on subjective experiences to initial cigarette use. Haberstick B.C., Ehringer M.A., Lessem J.M., Hopfer C.J., Hewitt J.K., p. 391-399.
• The relationship between addiction and reward bundling: an experiment comparing smokers and non-smokers. Hofmeyr A., Ainslie G., Charlton R., Ross D., p. 402-409.
• Does extinction of responses to cigarette cues occur during smoking cessation? O'Connell K.A., Shiffman S., Decarlo L.T., p. 410-417.
• Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Piper M.E., Cook J.W., Schlam T.R., Jorenby D.E., Baker T.B., p. 418-427.
• Teaching community program clinicians motivational interviewing using expert and train-the-trainer strategies. Martino S., Ball S.A., Nich C., Canning-Ball M., Rounsaville B.J., Carroll K.M., p. 428-441.
• Gamma-butyrolactone (GBL) dependence and withdrawal. Bell J., Collins R., p. 442-447.
• Questionable conclusions on cannabis and crime. Bretteville-Jensen A.L., Rossow I., p. 449-450; author reply 450-441.
• Australia's experience with varenicline: usage, costs and adverse reactions. Walsh R.A., p. 451-452.
• Proposals to trial deep brain stimulation to treat addiction are premature. Carter A., Hall W., p. 235-237.
• FOR DEBATE: The 'grass ceiling': limitations in the literature hinder our understanding of cannabis use and its consequences. Temple E.C., Brown R.F., Hine D.W., p. 238-244.
• Addiction research centres and the nurturing of creativity. RAND's Drug Policy Research Center. Reuter P., Pacula R.L., Caulkins J.P., p. 253-259.
• Conversation with Martin Jarvis. Jarvis M., p. 260-266.
• Can stand-alone computer-based interventions reduce alcohol consumption? A systematic review. Khadjesari Z., Murray E., Hewitt C., Hartley S., Godfrey C., p. 267-282.
• Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Ambermoon P., Carter A., Hall W.D., Dissanayaka N.N., O'Sullivan J.D., p. 283-293.
• How best to measure change in evaluations of treatment for substance use disorder. Marsden J., Eastwood B., Wright C., Bradbury C., Knight J., Hammond P., p. 294-302.
• Effects of restricting pub closing times on night-time assaults in an Australian city. Kypri K., Jones C., McElduff P., Barker D., p. 303-310.
• Per capita alcohol consumption and ischemic heart disease mortality in a panel of US states from 1950 to 2002. Kerr W.C., Karriker-Jaffe K., Subbaraman M., Ye Y., p. 313-322.
• Personal, family and social functioning among older couples concordant and discordant for high-risk alcohol consumption. Moos R.H., Schutte K.K., Brennan P.L., Moos B.S., p. 324-334.
• The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time. Howland J., Rohsenow D.J., Arnedt J.T., Bliss C.A., Hunt S.K., Calise T.V., et al., p. 335-341.
• The course of substance use disorders in patients with borderline personality disorder and Axis II comparison subjects: a 10-year follow-up study. Zanarini M.C., Frankenbur F.R., Weingeroff J.L., Reich D.B., Fitzmaurice G.M., Weiss R.D., p. 342-348.
• Decreased bone density in men on methadone maintenance therapy. Grey A., Rix-Trott K., Horne A., Gamble G., Bolland M., Reid I.R., p. 349-354.
• The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs. Beletsky L., Grau L.E., White E., Bowman S., Heimer R., p. 357-365.
• The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Tobin K.E., Kuramoto S.J., Davey-Rothwell M.A., Latkin C.A., p. 366-375.
• Cessation of groin injecting behaviour among patients on oral opioid substitution treatment. Senbanjo R., Hunt N., Strang J., p. 376-382.
• Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Linnet J., Moller A., Peterson E., Gjedde A., Doudet D., p. 383-390.
• Dizziness and the genetic influences on subjective experiences to initial cigarette use. Haberstick B.C., Ehringer M.A., Lessem J.M., Hopfer C.J., Hewitt J.K., p. 391-399.
• The relationship between addiction and reward bundling: an experiment comparing smokers and non-smokers. Hofmeyr A., Ainslie G., Charlton R., Ross D., p. 402-409.
• Does extinction of responses to cigarette cues occur during smoking cessation? O'Connell K.A., Shiffman S., Decarlo L.T., p. 410-417.
• Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Piper M.E., Cook J.W., Schlam T.R., Jorenby D.E., Baker T.B., p. 418-427.
• Teaching community program clinicians motivational interviewing using expert and train-the-trainer strategies. Martino S., Ball S.A., Nich C., Canning-Ball M., Rounsaville B.J., Carroll K.M., p. 428-441.
• Gamma-butyrolactone (GBL) dependence and withdrawal. Bell J., Collins R., p. 442-447.
• Questionable conclusions on cannabis and crime. Bretteville-Jensen A.L., Rossow I., p. 449-450; author reply 450-441.
• Australia's experience with varenicline: usage, costs and adverse reactions. Walsh R.A., p. 451-452.
Dépouillements
Ajouter le résultat à votre sélection
E. C. TEMPLE ;
R. F. BROWN ;
D. W. HINE
|
2011
Dans Addiction (Vol.106, n°2, February 2011) Article : Périodique
Dans Addiction (Vol.106, n°2, February 2011) Article : Périodique
AIM: To illustrate how limitations in the cannabis literature undermine our ability to understand cannabis-related harms and problems experienced by users and identify users at increased risk of experiencing adverse outcomes of use.
METHOD AND[...]
AIM: To describe morbidity associated with gamma-butyrolactone (GBL) dependence, and outcomes of withdrawal.
DESIGN: Case series.
SETTING: Specialist out-patient clinic and affiliated in-patient detoxification unit. Patients with home suppor[...]
W. C. KERR ;
K. KARRIKER-JAFFE ;
M. SUBBARAMAN ;
Y. YE
|
2011
Dans Addiction (Vol.106, n°2, February 2011) Article : Périodique
Dans Addiction (Vol.106, n°2, February 2011) Article : Périodique
AIMS: To estimate the overall impact of alcohol on ischemic heart disease (IHD) mortality in the United States using aggregate-level models and to consider beverage-specific effects that may represent more effectively the changes in drinking pat[...]